Download Free Novel Targets In The Treatment Of Inflammatory Bowel Disease Book in PDF and EPUB Free Download. You can read online Novel Targets In The Treatment Of Inflammatory Bowel Disease and write the review.

This Research Topic is part of a series with: Novel Targets for Chronic Inflammatory Diseases: Focus On Therapeutic Drugs and Natural Compounds Chronic inflammation is a component of many disease conditions that affect a large group of individuals worldwide, which is characterized by persistent, low-grade inflammation and is increased in the aging population. It occurs when an initiating stimulus is not removed or if the resolution process is disrupted, resulting in a state of low-grade inflammation. It is acknowledged that chronic inflammatory diseases are involved in cardiovascular diseases, endocrine disease, neurodegenerative disease, hepatic disease, pulmonary disease, gastrointestinal disease, and cancer et al., including but not limited to atherosclerosis, diabetes, multiple sclerosis, fibrosis, NAFLD, COPD, inflammatory bowel disease, autoimmune disorders(like SLE, RA), which are major causes of death worldwide. Immunity is a physiological function of the human body, which maintains health by destroying and rejecting foreign substances including antigens, damaged cells, and tumors et al. There is a close relationship between inflammation and immunity, whether they are both protective mechanisms against invasion or injury responses. Therefore, the important role of inflammatory and immune responses should be noted, it is necessary to explore novel targets and therapeutic drugs for chronic inflammatory diseases.
Chronic inflammation is a component of many disease conditions that affect a large group of individuals worldwide, which is characterized by persistent, low-grade inflammation and is increased in the aging population. It occurs when an initiating stimulus is not removed or if the resolution process is disrupted, resulting in a state of low-grade inflammation. It is acknowledged that chronic inflammatory diseases are involved in cardiovascular diseases, endocrine disease, neurodegenerative disease, hepatic disease, pulmonary disease, gastrointestinal disease, and cancer et al., including but not limited to atherosclerosis, diabetes, multiple sclerosis, fibrosis, NAFLD, COPD, inflammatory bowel disease, autoimmune disorders (like SLE, RA), which are major causes of death worldwide. Therefore, it is necessary to explore novel targets and therapeutic drugs for chronic inflammatory diseases.
Written by known specialists in the field, this is a comprehensive and timely overview of a central and expanding topic. Simultaneously an introduction and a description of the latest concepts, findings and methods, the handbook provides basic knowledge on technical issues required for those intending to research in the field. It covers the functional role of involved molecules and the cellular mechanisms, and addresses selected examples for their possible application in therapy -- bridging the gap between trafficking mechanisms and novel therapeutic strategies. In addition, it includes selection of proven and timesaving methods for studying cell trafficking in vitro and in vivo. The accompanying CD-ROM makes leukocyte migration videos available to a broad audience for the first time.
The first gene responsible for Crohn's disease has now been identified and the pathophysiological understanding of inflammatory bowel disease as well as its practical treatment have made much progress in recent years. Thus it is obviously important to consider the targets and the aims of treatment in context. The Falk Symposium No. 131 (Part II of the Gastroenterology Week Freiburg 2002), held in October 2002 in Freiburg, Germany, in its first part was dedicated to newly defined and partly alternative therapeutic targets. In addition, an attempt was made to learn from experts from other fields such as pneumology or dermatology. The second part was dedicated to the aims of treatment in daily practice. Aside from general treatment, aims such as amelioration of symptoms, pre-conditions of treatment, the view of the patients, and aspects of life quality were dealt with. This volume is the proceedings of the symposium and is important reading for both clinicians and basic scientists.
Inflammatory bowel diseases (IBD), are chronic and progressive diseases. Long-term complications are demolition surgery and colon-rectal cancer (CRC). A treat-to-target approach aims to modify the natural course of these diseases. Targets are pre-defined therapeutic goals demonstrated to prevent end-organ disfunction and disability in the long-term period. According to the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) indications, mucosal healing (MH) and clinical remission are the main targets in IBDs. Recently, the concept of remission and evidence on new targets included histological remission and transmural healing as future new targets. It remains controversial whether achieving these targets is associated with significantly better long-term disease outcomes. In this Research Topic, we aim to systematically review current evidence and future perspectives on therapeutic targets in IBD including mucosal and transmural healing.
This unique book deals with both inflammation and cancer in a single source of publication. They are seldom grouped together although it has been known that both diseases are closely associated, particularly in the gastrointestinal tract and liver. As the book touches on two such major areas of diseases in humans, it should be of interest to a wider audience of researchers and readers. It is noted that the book combines the effort of both basic scientists and clinicians from different countries with extensive experiences in molecular biology and clinical practice to unveil the most updated picture of the pathogenesis and therapeutic strategies in the treatment of inflammation and cancer in the digestive tract. In this regard, potential pathogenic modulators and also therapeutic options are widely discussed. These types of information would definitely broaden our knowledge in better understanding these diseases.
Now published in two volumes to accommodate new chapters on the many advances in understanding and treatment options, this set of volumes represents the definitive reference on inflammatory bowel disease, a spectrum of diseases that is receiving increasing attention as our understanding of the etiological factors increases and diagnostic tools are refined. Basic research accelerated at the beginning of this decade and is now yielding new, more targeted treatments than were available just a few years ago. Volume 1 is on IBD and Ulcerative Colitis, and Volume 2 is on IBD and Crohn's Disease. All areas that were covered in the 2nd edition have been expanded and updated. New sections include the rapidly expanding knowledge of genetics and the role of the intestinal flora and environmental factors in etiology and pathogenesis. Among the 168 chapters, there are 20 on biologic therapies and 30 on surgical management. The consultant/authors clearly state their approach to important issues, such as the duration of immunomodulator and of anti-TNF-a use and the options for managing isolated low-grade dysplasia. A strong focus on the individual patient is woven throughout both volumes, including the benefits and risks of potentially life-altering therapies and surgeries. Entire sections detail concerns about the well-being of each person. This book provides information for health professionals who help both pediatric and adult patients navigate through the lifelong shadow of a chronic, probably genetically determined ordeal.